Global Next-Generation Breast Cancer Diagnostic and Screening Market: Focus on Products, Technologies, Cancer Sub-Type, End Users, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Market Report Coverage - Next Generation Breast Cancer Diagnostic and Screening
Market Segmentation
Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Invitae Corporation, Thermo Fisher Scientific Inc., Biocept, Inc., Biotheranostics, Agendia N.V., Lucence Diagnostics Pte Ltd, Agilent Technologies, Inc., Myriad Genetics, Inc, Fulgent Genetics, Centogene N.V., and Ambry Genetics
Key Questions Answered in this Report:
Our healthcare experts have found next generation breast cancer diagnostics and screening market to be one of the most rapidly evolving markets and the global market for next generation breast cancer diagnostics and screening market is predicted to grow at a CAGR of 13.12% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising incidence of breast cancer patients inciting the development of rapid diagnostic assays, significant innovation resulting in market pull, shift from centralized to decentralized laboratories, and significant external funding for executing R&D exercises.
The market is favoured by the development of genomic-based assays for early diagnosis and prognosis of metastatic and recurrent breast cancers. The gradual increase in the prevalence of breast cancer patients, globally has furthered the breast cancer diagnostics market.
Furthermore, several diagnostic companies are focusing on the development of biomarker-diagnostics with higher sensitivity and low turn-around time to benefit the patients, providing diagnosis at an early stage.
Within the research report, the market is segmented on the basis of product type, application, technology, disease end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of rapid diagnostics providing information on genetic mutation and patients good candidate for adjuvant chemotherapy or hormonal therapy. Due to the diverse product portfolio and intense market penetration, Abbott Laboratories has been a pioneer in this field and been a significant competitor in this market.
Several other companies such as F. Hoffman-La Roche Ltd, Myriad Genetics Inc., and Agendia, among others, have launched diagnostics assays for breast cancer, such as Foundation One CDx, EndoPredict, and Mammaprint, among others.
On the basis of region, North America holds the largest share of next generation breast cancer diagnostics and screening market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.
Market Report Coverage - Next Generation Breast Cancer Diagnostic and Screening
Market Segmentation
- Product Type - BRCA tests, ER/PR tests, HER2 tests
- Technology- Real-Time Polymerase Chain Reaction (RT-PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Next-Generation Sequencing and Others
- Cancer Subtype - Luminal A, Luminal B, Triple negative/basal like, Human Epidermal Growth Factor (HER2)
- End User - Hospital associated lab, Cancer Research Institutes, Diagnostic Centers, and Other End Users
- North America – U.S., Canada
- Europe – Germany, France, Italy, U.K., Spain, and Rest-of-Europe
- Asia-Pacific – China, Japan, India, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)
- Latin America – Brazil, Mexico, and Rest-of-the-Latin America
- Rest-of-the-World
- Increasing Prevalence of Breast Cancer, Globally
- Increase in Adoption of Personalized Medicine for the Screening and Diagnostics of Breast Cancer
- Growing Focus on Breast Cancer Biomarker for Effective Screening and Prognosis
- Uncertain Reimbursement Policies Pertaining to Breast Cancer Molecular Diagnostics
- Requirement of High Capital Investment Hindering Expansion
- Issues Related to Clinical Validity of Biomarker-based Tests
- Massive Scope for Adoption of Breast Cancer Molecular Diagnostics in Emerging Nations
- Technological Advancements in the development of Next Generation Breast Cancer Diagnostics
- Increased Use of Breast Cancer Diagnostics for the Development of Therapeutics Drugs and Comprehensive Treatment Plan
Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Invitae Corporation, Thermo Fisher Scientific Inc., Biocept, Inc., Biotheranostics, Agendia N.V., Lucence Diagnostics Pte Ltd, Agilent Technologies, Inc., Myriad Genetics, Inc, Fulgent Genetics, Centogene N.V., and Ambry Genetics
Key Questions Answered in this Report:
- What are the major market drivers, challenges, and opportunities in the next generation breast cancer diagnosis and screening market?
- What is the potential impact of COVID-19 on the breast cancer diagnosis in terms of availability of resources such as physicians, laboratory staff and technological advancements?
- What are the noticeable drifts across various regional markets amidst the COVID-19 pandemic on the early stage screening of breast cancer?
- What is the current market demand along with future expected demand trend of Next generation breast cancer diagnostics services for various subtypes.?
- How the next generation diagnostics have helped genomic tests to become a prominent tool for breast cancer screening rather than an adjunct diagnostic tool?
- What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?
- What are the key technologies that have been used by leading players in the market for the development of molecular diagnostic assays for early breast cancer screening and diagnosis?
- How each segment of the market is expected to grow during the forecast period from 2020 to 2030 based on:
- Technology
- Assay Type
- Breast Cancer Subtypes
- Diagnostic Type
- End user
- Region: Region includes North America, Europe, Asia-Pacific, Rest-of-the-World (ROW)
- Who are the leading players with significant offerings to the next generation breast cancer diagnosis and screening market? What is the expected market dominance for each of these leading players?
- Which companies are anticipated to be highly disruptive in the future and why?
Our healthcare experts have found next generation breast cancer diagnostics and screening market to be one of the most rapidly evolving markets and the global market for next generation breast cancer diagnostics and screening market is predicted to grow at a CAGR of 13.12% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising incidence of breast cancer patients inciting the development of rapid diagnostic assays, significant innovation resulting in market pull, shift from centralized to decentralized laboratories, and significant external funding for executing R&D exercises.
The market is favoured by the development of genomic-based assays for early diagnosis and prognosis of metastatic and recurrent breast cancers. The gradual increase in the prevalence of breast cancer patients, globally has furthered the breast cancer diagnostics market.
Furthermore, several diagnostic companies are focusing on the development of biomarker-diagnostics with higher sensitivity and low turn-around time to benefit the patients, providing diagnosis at an early stage.
Within the research report, the market is segmented on the basis of product type, application, technology, disease end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of rapid diagnostics providing information on genetic mutation and patients good candidate for adjuvant chemotherapy or hormonal therapy. Due to the diverse product portfolio and intense market penetration, Abbott Laboratories has been a pioneer in this field and been a significant competitor in this market.
Several other companies such as F. Hoffman-La Roche Ltd, Myriad Genetics Inc., and Agendia, among others, have launched diagnostics assays for breast cancer, such as Foundation One CDx, EndoPredict, and Mammaprint, among others.
On the basis of region, North America holds the largest share of next generation breast cancer diagnostics and screening market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.
EXECUTIVE SUMMARY
1 PRODUCT DEFINITION
1.1 Definition by Products
1.1.1 Assays
1.2 Inclusion and Exclusion
2 MARKET SCOPE
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Market Estimation Model
4 MARKET OVERVIEW
4.1 Introduction
4.2 Implementation of Precision Medicine in Breast Cancer Diagnostics
4.3 Impact of COVID-19 on Delivery of Care for Cancer Patients
4.4 Breast Cancer Clinical Trials
5 NEXT-GENERATION BREAST CANCER DIAGNOSTICS AND SCREENING MARKET DYNAMICS
5.1 Overview
5.2 Impact Analysis
5.3 Market Drivers
5.3.1 Increasing Prevalence of Breast Cancer Globally
5.3.2 Increasing Adoption of Personalized Medicine for Screening and Diagnostics of Breast Cancer
5.3.3 Growing Focus on Breast Cancer Biomarker for Effective Screening and Prognosis
5.4 Market Restraints
5.4.1 Uncertain Reimbursement Policies Pertaining to Breast Cancer Molecular Diagnostics
5.4.2 Unavailability of High Capital Investment Hindering Expansion
5.4.3 Issues Related to Clinical Validity of Biomarker-Based Tests
5.5 Market Opportunities
5.5.1 Massive Scope for Adoption of Breast Cancer Molecular Diagnostics in Emerging Nations
5.5.2 Technological Advancements in the Development of Next-Generation Breast Cancer Diagnostics
5.5.3 Increased Use of Breast Cancer Diagnostics for the Development of Therapeutics Drugs and Comprehensive Treatment Plan
6 COMPETITIVE LANDSCAPE
6.1 Key Strategies and Developments
6.1.1 Product Approvals
6.1.2 Product Launches and Upgradations
6.1.3 Synergistic Activities
6.1.4 Funding and Expansion
6.1.5 Mergers and Acquisitions
6.1.6 Other
6.2 Market Share Analysis (by Company), 2019
6.3 Growth Share Analysis (Opportunity Mapping)
6.3.1 By Company
7 NEXT-GENERATION BREAST CANCER DIAGNOSTICS AND SCREENING MARKET (BY TECHNOLOGY), 2019-2030
7.1 Overview
7.2 Real-Time PCR (q-PCR)
7.3 Immunohistochemistry (IHC)
7.4 Next-Generation Sequencing (NGS)
7.5 Fluorescent In-Situ Hybridization (FISH)
7.6 Other
8 NEXT-GENERATION BREAST CANCER DIAGNOSTICS AND SCREENING MARKET (BY CANCER SUBTYPE) 2019-2030
8.1 Overview
8.2 Luminal A
8.3 Luminal B
8.4 Triple-Negative/Basal-Like
8.5 Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched
9 NEXT-GENERATION BREAST CANCER DIAGNOSTICS AND SCREENING MARKET (BY TEST TYPE) 2019-2030
9.1 Overview
9.2 BRCA Test
9.3 ER/PR Receptors
9.4 HER-2 Tests
9.5 Other
10 NEXT-GENERATION BREAST CANCER DIAGNOSTIC AND SCREENING MARKET (BY REGION) 2019-2030
10.1 Overview
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest-of-Europe
10.4 Asia-Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 Singapore
10.4.6 Rest-of-APAC
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest-of-Latin America
10.6 Rest-of-the-World
11 NEXT-GENERATION BREAST CANCER DIAGNOSTICS AND SCREENING MARKET (BY END USER), 2019-2030
11.1 Overview
11.2 Hospital-associated Labs
11.3 Cancer Research Institutes
11.4 Diagnostic Centers
11.5 Other End Users
12 COMPANY PROFILES
12.1 Overview
12.2 Abbott Laboratories
12.2.1 Company Overview
12.2.2 Role of Abbott Laboratories in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.2.3 Financials
12.2.3.1 Key Insights About Financial Health of the Company
12.2.4 SWOT Analysis
12.3 Agendia
12.3.1 Company Overview
12.3.2 Role of Agendia in Next-Generation Breast Cancer Diagnostic and Screening Market
12.3.3 SWOT Analysis
12.4 Agilent Technologies, Inc.
12.4.1 Company Overview
12.4.2 Role of Agilent Technologies, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.4.3 Financials
12.4.3.1 Key Insights About Financial Health of the Company
12.4.4 SWOT Analysis
12.5 Ambry Genetics
12.5.1 Company Overview
12.5.2 Role of the Ambry Genetics in the Next-Generation Diagnostic and Screening Market
12.5.3 SWOT Analysis
12.6 Biocept, Inc.
12.6.1 Company Overview
12.6.2 Role of Biocept, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.6.3 Financials
12.6.3.1 Key Insights About Financial Health of the Company
12.6.4 SWOT Analysis
12.7 Biotheranostics, Inc.
12.7.1 Company Overview
12.7.2 Role of the Biotheranostics, Inc. in the Next-Generation Diagnostic and Screening Market
12.7.3 SWOT Analysis
12.8 CENTOGENE N.V.
12.8.1 Company Overview
12.8.2 Role of CENTOGENE N.V. in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.8.3 Financials
12.8.3.1 Key Insights About Financial Health of the Company
12.8.4 SWOT Analysis
12.9 Danaher Corporation
12.9.1 Company Overview
12.9.2 Role of Danaher Corporation in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.9.3 Financials
12.9.3.1 Key Insights About Financial Health of the Company
12.9.4 SWOT Analysis
12.1 Exact Sciences Corporation
12.10.1 Company Overview
12.10.2 Role of Exact Sciences Corporation in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.10.3 Financials
12.10.3.1 Key Insights About Financial Health of the Company
12.10.4 SWOT Analysis
12.11 F. Hoffmann-La Roche Ltd.
12.11.1 Company Overview
12.11.2 Role of F. Hoffmann-La Roche Ltd. in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.11.3 Financials
12.11.3.1 Key Insights About Financial Health of the Company
12.11.4 SWOT Analysis
12.12 Fulgent Genetics
12.12.1 Company Overview
12.12.2 Role of Fulgent Genetics in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.12.3 Financials
12.12.3.1 Key Insights About Financial Health of the Company
12.12.4 SWOT Analysis
12.13 Illumina, Inc.
12.13.1 Company Overview
12.13.2 Role of Illumina, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.13.3 Financials
12.13.3.1 Key Insights about Financial Health of the Company
12.13.4 SWOT Analysis
12.14 Invitae Corporation
12.14.1 Company Overview
12.14.2 Role of Invitae Corporation, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.14.3 Financials
12.14.3.1 Key Insights About Financial Health of the Company
12.14.4 SWOT Analysis
12.15 Lucence Diagnostics Pte Ltd
12.15.1 Company Overview
12.15.2 Role of the Lucene Diagnostic Pte Ltd in Next-Generation Breast Cancer Diagnostic and Screening Market
12.15.3 SWOT Analysis
12.16 Myriad Genetics, Inc.
12.16.1 Company Overview
12.16.2 Role of Myriad Genetics, Inc. in the Next-Generation Breast Cancer Diagnostic Market
12.16.3 Financials
12.16.3.1 Key Insights About Financial Health of the Company
12.16.4 SWOT Analysis
1 PRODUCT DEFINITION
1.1 Definition by Products
1.1.1 Assays
1.2 Inclusion and Exclusion
2 MARKET SCOPE
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Market Estimation Model
4 MARKET OVERVIEW
4.1 Introduction
4.2 Implementation of Precision Medicine in Breast Cancer Diagnostics
4.3 Impact of COVID-19 on Delivery of Care for Cancer Patients
4.4 Breast Cancer Clinical Trials
5 NEXT-GENERATION BREAST CANCER DIAGNOSTICS AND SCREENING MARKET DYNAMICS
5.1 Overview
5.2 Impact Analysis
5.3 Market Drivers
5.3.1 Increasing Prevalence of Breast Cancer Globally
5.3.2 Increasing Adoption of Personalized Medicine for Screening and Diagnostics of Breast Cancer
5.3.3 Growing Focus on Breast Cancer Biomarker for Effective Screening and Prognosis
5.4 Market Restraints
5.4.1 Uncertain Reimbursement Policies Pertaining to Breast Cancer Molecular Diagnostics
5.4.2 Unavailability of High Capital Investment Hindering Expansion
5.4.3 Issues Related to Clinical Validity of Biomarker-Based Tests
5.5 Market Opportunities
5.5.1 Massive Scope for Adoption of Breast Cancer Molecular Diagnostics in Emerging Nations
5.5.2 Technological Advancements in the Development of Next-Generation Breast Cancer Diagnostics
5.5.3 Increased Use of Breast Cancer Diagnostics for the Development of Therapeutics Drugs and Comprehensive Treatment Plan
6 COMPETITIVE LANDSCAPE
6.1 Key Strategies and Developments
6.1.1 Product Approvals
6.1.2 Product Launches and Upgradations
6.1.3 Synergistic Activities
6.1.4 Funding and Expansion
6.1.5 Mergers and Acquisitions
6.1.6 Other
6.2 Market Share Analysis (by Company), 2019
6.3 Growth Share Analysis (Opportunity Mapping)
6.3.1 By Company
7 NEXT-GENERATION BREAST CANCER DIAGNOSTICS AND SCREENING MARKET (BY TECHNOLOGY), 2019-2030
7.1 Overview
7.2 Real-Time PCR (q-PCR)
7.3 Immunohistochemistry (IHC)
7.4 Next-Generation Sequencing (NGS)
7.5 Fluorescent In-Situ Hybridization (FISH)
7.6 Other
8 NEXT-GENERATION BREAST CANCER DIAGNOSTICS AND SCREENING MARKET (BY CANCER SUBTYPE) 2019-2030
8.1 Overview
8.2 Luminal A
8.3 Luminal B
8.4 Triple-Negative/Basal-Like
8.5 Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched
9 NEXT-GENERATION BREAST CANCER DIAGNOSTICS AND SCREENING MARKET (BY TEST TYPE) 2019-2030
9.1 Overview
9.2 BRCA Test
9.3 ER/PR Receptors
9.4 HER-2 Tests
9.5 Other
10 NEXT-GENERATION BREAST CANCER DIAGNOSTIC AND SCREENING MARKET (BY REGION) 2019-2030
10.1 Overview
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest-of-Europe
10.4 Asia-Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 Singapore
10.4.6 Rest-of-APAC
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest-of-Latin America
10.6 Rest-of-the-World
11 NEXT-GENERATION BREAST CANCER DIAGNOSTICS AND SCREENING MARKET (BY END USER), 2019-2030
11.1 Overview
11.2 Hospital-associated Labs
11.3 Cancer Research Institutes
11.4 Diagnostic Centers
11.5 Other End Users
12 COMPANY PROFILES
12.1 Overview
12.2 Abbott Laboratories
12.2.1 Company Overview
12.2.2 Role of Abbott Laboratories in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.2.3 Financials
12.2.3.1 Key Insights About Financial Health of the Company
12.2.4 SWOT Analysis
12.3 Agendia
12.3.1 Company Overview
12.3.2 Role of Agendia in Next-Generation Breast Cancer Diagnostic and Screening Market
12.3.3 SWOT Analysis
12.4 Agilent Technologies, Inc.
12.4.1 Company Overview
12.4.2 Role of Agilent Technologies, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.4.3 Financials
12.4.3.1 Key Insights About Financial Health of the Company
12.4.4 SWOT Analysis
12.5 Ambry Genetics
12.5.1 Company Overview
12.5.2 Role of the Ambry Genetics in the Next-Generation Diagnostic and Screening Market
12.5.3 SWOT Analysis
12.6 Biocept, Inc.
12.6.1 Company Overview
12.6.2 Role of Biocept, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.6.3 Financials
12.6.3.1 Key Insights About Financial Health of the Company
12.6.4 SWOT Analysis
12.7 Biotheranostics, Inc.
12.7.1 Company Overview
12.7.2 Role of the Biotheranostics, Inc. in the Next-Generation Diagnostic and Screening Market
12.7.3 SWOT Analysis
12.8 CENTOGENE N.V.
12.8.1 Company Overview
12.8.2 Role of CENTOGENE N.V. in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.8.3 Financials
12.8.3.1 Key Insights About Financial Health of the Company
12.8.4 SWOT Analysis
12.9 Danaher Corporation
12.9.1 Company Overview
12.9.2 Role of Danaher Corporation in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.9.3 Financials
12.9.3.1 Key Insights About Financial Health of the Company
12.9.4 SWOT Analysis
12.1 Exact Sciences Corporation
12.10.1 Company Overview
12.10.2 Role of Exact Sciences Corporation in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.10.3 Financials
12.10.3.1 Key Insights About Financial Health of the Company
12.10.4 SWOT Analysis
12.11 F. Hoffmann-La Roche Ltd.
12.11.1 Company Overview
12.11.2 Role of F. Hoffmann-La Roche Ltd. in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.11.3 Financials
12.11.3.1 Key Insights About Financial Health of the Company
12.11.4 SWOT Analysis
12.12 Fulgent Genetics
12.12.1 Company Overview
12.12.2 Role of Fulgent Genetics in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.12.3 Financials
12.12.3.1 Key Insights About Financial Health of the Company
12.12.4 SWOT Analysis
12.13 Illumina, Inc.
12.13.1 Company Overview
12.13.2 Role of Illumina, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.13.3 Financials
12.13.3.1 Key Insights about Financial Health of the Company
12.13.4 SWOT Analysis
12.14 Invitae Corporation
12.14.1 Company Overview
12.14.2 Role of Invitae Corporation, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
12.14.3 Financials
12.14.3.1 Key Insights About Financial Health of the Company
12.14.4 SWOT Analysis
12.15 Lucence Diagnostics Pte Ltd
12.15.1 Company Overview
12.15.2 Role of the Lucene Diagnostic Pte Ltd in Next-Generation Breast Cancer Diagnostic and Screening Market
12.15.3 SWOT Analysis
12.16 Myriad Genetics, Inc.
12.16.1 Company Overview
12.16.2 Role of Myriad Genetics, Inc. in the Next-Generation Breast Cancer Diagnostic Market
12.16.3 Financials
12.16.3.1 Key Insights About Financial Health of the Company
12.16.4 SWOT Analysis
LIST OF TABLES
Table 4.1: Breast Cancer Clinical Trials
Table 5.1: Likert Scale
Table 5.2: Impact Analysis of Market Drivers
Table 5.3: Impact Analysis of Market Restraints
Table 7.1: Key Products Offered Based on RT-PCR
Table 7.2: Key Products Offered Based on IHC
Table 7.3: Key Products Offered Based on NGS
Table 7.4: Key Products Offered Based on FISH
Table 7.5: Key Products Offered Based on Other Technology
Table 9.1: Key Products Offered Based on BRCA Test
Table 9.2: Key Products Offered Based on ER/PR Test
Table 9.3: Key Products Offered Based on HER-2
Table 4.1: Breast Cancer Clinical Trials
Table 5.1: Likert Scale
Table 5.2: Impact Analysis of Market Drivers
Table 5.3: Impact Analysis of Market Restraints
Table 7.1: Key Products Offered Based on RT-PCR
Table 7.2: Key Products Offered Based on IHC
Table 7.3: Key Products Offered Based on NGS
Table 7.4: Key Products Offered Based on FISH
Table 7.5: Key Products Offered Based on Other Technology
Table 9.1: Key Products Offered Based on BRCA Test
Table 9.2: Key Products Offered Based on ER/PR Test
Table 9.3: Key Products Offered Based on HER-2
LIST OF FIGURES
Figure 1: Worldwide Breast Cancer Statistics (by Region), 2018
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Next-Generation Breast Cancer Diagnostics and Screening Market
Figure 3: Next-Generation Breast Cancer Diagnostics and Screening Market (by Product Type), ($Million), 2020 vs 2030
Figure 4: Next-Generation Breast Cancer Diagnostics and Screening Market (by Technology), ($Million), 2020 vs. 2030
Figure 5: Next-GenerationNext-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Subtype), ($Million), 2020 vs. 2030
Figure 6: Next-Generation Breast Cancer Diagnostics and Screening Market (by End User), ($Million), 2020 vs. 2030
Figure 7: Next-Generation Breast Cancer Diagnostics and Screening Market Snapshot
Figure 2.1: Next-Generation Breast Cancer Diagnostics and Screening Segmentation
Figure 3.1: Primary Research Methodology
Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
Figure 5.1: Number of Cases (in Million) by Different Forms of Cancer, 2018
Figure 5.2: Global Incidence of Breast Cancer Cases, As of 2018
Figure 6.1: Share of Key Developments and Strategies, 2017-2020
Figure 6.2: Product Approval Share (by Company), 2017–2020
Figure 6.3: Product Launch and Upgradation Share (by Company), 2017–2020
Figure 6.4: Synergistic Activities Share (by Company), 2017-2020
Figure 6.5: Funding and Expansion Share (by Company), 2017-2020
Figure 6.6: Mergers and Acquisitions Share (by Company), 2017-2020
Figure 6.7: Other Key Development Share (by Company), 2017-2020
Figure 6.8: Market Share Analysis for the Next-Generation Breast Cancer Diagnostics and Screening Market, 2019
Figure 6.9: Growth Share Matrix for Next-Generation Breast Cancer Diagnostics and Screening (by Company), 2019
Figure 7.1: Next-Generation Breast Cancer Diagnostics and Screening Market (by Technology), ($Million), 2019-2030
Figure 7.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (RT-PCR), ($Million), 2019-2030
Figure 7.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (IHC), ($Million), 2019-2030
Figure 7.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (NGS), ($Million), 2019-2030
Figure 7.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (FISH), (($Million)), 2019-2030
Figure 7.6: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Other), 2019-2030 ($ Million)
Figure 8.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Subtype), ($Million), 2019-2030
Figure 8.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Luminal A), ($Million), 2019-2030
Figure 8.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Luminal B), ($Million), 2019-2030
Figure 8.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Triple-negative/basal-like), ($Million), 2019-2030
Figure 8.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (by HER-2 Enriched), ($Million), 2019-2030
Figure 9.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by Test Type),($Million), 2019-2030
Figure 9.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (BRCA), ($Million), 2019-2030
Figure 9.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (ER/PR Receptor), ($Million), 2019-2030
Figure 9.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (HER-2), ($Million), 2019-2030
Figure 9.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (by Other), ($Million), 2019-2030
Figure 10.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), ($Million), 2020 and 2030
Figure 10.2: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), ($Million), 2019-2030
Figure 10.3: North America Next-Generation Breast Cancer Diagnostic and Screening Market, (($Million)), 2019-2030
Figure 10.4: North America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), ($Million), 2019-2030
Figure 10.5: North America: Market Dynamics
Figure 10.6: U.S. Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
Figure 10.7: Canada Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
Figure 10.8: Europe Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.9: Europe: Market Dynamics
Figure 10.10: Europe Next-Generation Breast Cancer Diagnostics and Screening Market (by Country), ($Million), 2019-2030
Figure 10.11: Germany Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.12: U.K. Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.13: France Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.14: Italy Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.15: Spain Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.16: Rest-of-Europe Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.17: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030,
Figure 10.18: APAC: Market Dynamics
Figure 10.19: APAC Global Next-Generation Breast Cancer Diagnostics and Screening Market (by Country), ($Million), 2019-2030
Figure 10.20: China Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.21: Japan Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.22: India Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.23: Australia Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.24: Singapore Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.25: RoAPAC Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.26: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
Figure 10.27: Latin America: Market Dynamics
Figure 10.28: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), ($Million), 2019-2030
Figure 10.29: Brazil Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million) 2019-2030,
Figure 10.30: Mexico Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030,
Figure 10.31: Rest-of-Latin America Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million) 2019-2030
Figure 10.32: RoW Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030,
Figure 11.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by End User), ($Million), 2019-2030
Figure 11.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Hospital-associated labs), 2019-2030 ($ Million)
Figure 11.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Cancer Research Institutes), ($Million), 2019-2030
Figure 11.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Diagnostic Centers), ($Million), 2019-2030
Figure 11.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (by Other End Users), 2019-2030
Figure 12.1: Total Number of Companies Profiled
Figure 12.2: Abbott Laboratories: Portfolio
Figure 12.3: Abbott Laboratories: Overall Financials, 2017-2019
Figure 12.4: Abbott Laboratories: Revenue (by Segment), 2017-2019
Figure 12.5: Abbott Laboratories: Revenue Split for Diagnostics, 2017-2019
Figure 12.6: Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 12.7: Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 12.8: Abbott Laboratories: SWOT Analysis
Figure 12.9: Agendia: Product Portfolio
Figure 12.10: Agendia: SWOT Analysis
Figure 12.11: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 12.12: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 12.13: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 12.14: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 12.15: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 12.16: Agilent Technologies, Inc.: SWOT Analysis
Figure 12.17: Ambry Genetics: Product portfolio
Figure 12.18: Ambry Genetics: SWOT Analysis
Figure 12.19: Biocept, Inc.: Portfolio
Figure 12.20: Biocept, Inc.: Overall Financials, 2017-2019
Figure 12.21: Biocept, Inc.: Sales (by Segment), 2017-2019
Figure 12.22: Biocept, Inc.: R&D Expenditure, 2017-2019
Figure 12.23: Biocept, Inc.: SWOT Analysis
Figure 12.24: Biotheranostics, Inc.: Product Portfolio
Figure 12.25: Biotheranostics, Inc.: SWOT Analysis
Figure 12.26: CENTOGENE N.V.: Overall Product Portfolio
Figure 12.27: CENTOGENE N.V.: Overall Financials, 2017-2019
Figure 12.28: CENTOGENE N.V.: Sales (by Segment), 2016-2018
Figure 12.29: CENTOGENE N.V.: Sales (by Region), 2017-2019
Figure 12.30: CENTOGENE N.V.: R&D Expenditure, 2017-2019
Figure 12.31: CENTOGENE N.V.: SWOT Analysis
Figure 12.32: Danaher Corporation: Product Portfolio
Figure 12.33: Danaher Corporation: Overall Financials, 2017-2019
Figure 12.34: Danaher Corporation: Revenue (by Business Segment), 2017-2019
Figure 12.35: Danaher Corporation: Revenue (by Region), 2017-2019
Figure 12.36: Danaher Corporation: R&D Expenditure, 2016-2018
Figure 12.37: Danaher Corporation: SWOT Analysis
Figure 12.38: Exact Science Corporation: Product Portfolio
Figure 12.39: Exact Sciences Corporation: Overall Financials, 2017-2019
Figure 12.40: Exact Sciences Corporation: Revenue (by Business Segment), 2017-2019
Figure 12.41: Exact Sciences Corporation: Revenue (by Region), 2017-2019
Figure 12.42: Exact Sciences Corporation: R&D Expenditure, 2017-2019
Figure 12.43: Exact Sciences Corporation: SWOT Analysis
Figure 12.44: F. Hoffmann-La Roche Ltd.: Portfolio
Figure 12.45: F. Hoffmann-La Roche Ltd.: Overall Financials, 2017-2019
Figure 12.46: F. Hoffmann-La Roche Ltd.: Sales (by Segment), 2017-2019
Figure 12.47: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
Figure 12.48: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2017-2019
Figure 12.49: F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 12.50: Fulgent Genetics: Product Portfolio
Figure 12.51: Fulgent Genetics: Overall Financials, 2017-2019
Figure 12.52: Fulgent Genetics: Revenue (by Business Segment), 2018-2019
Figure 12.53: Fulgent Genetics: Revenue (by Region), 2017-2019
Figure 12.54: Fulgent Genetics: R&D Expenditure, 2017-2019
Figure 12.55: Fulgent Genetics: SWOT Analysis
Figure 12.56: Illumina, Inc.: Portfolio
Figure 12.57: Illumina, Inc.: Overall Financials, 2017-2019
Figure 12.58: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 12.59: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 12.60: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 12.61: Illumina, Inc.: SWOT Analysis
Figure 12.62: Invitae Corporation: Overall Product Portfolio
Figure 12.63: Invitae Corporation: Overall Financials, 2017-2019
Figure 12.64: Invitae Corporation: Revenue (by Segment), 2017-2019
Figure 12.65: Invitae Corporation: Revenue (by Geography), 2017-2019
Figure 12.66: Invitae Corporation: R&D Expenditure, 2017-2019
Figure 12.67: Invitae Corporation: SWOT Analysis
Figure 12.68: Lucene Diagnostics Pte Ltd: Product Portfolio
Figure 12.69: Lucene Diagnostic Pte Ltd: SWOT Analysis
Figure 12.70: Myriad Genetics, Inc.: Overall Product Portfolio
Figure 12.71: Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 12.72: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.73: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 12.74: Myriad Genetics, Inc.: SWOT Analysis
Figure 1: Worldwide Breast Cancer Statistics (by Region), 2018
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Next-Generation Breast Cancer Diagnostics and Screening Market
Figure 3: Next-Generation Breast Cancer Diagnostics and Screening Market (by Product Type), ($Million), 2020 vs 2030
Figure 4: Next-Generation Breast Cancer Diagnostics and Screening Market (by Technology), ($Million), 2020 vs. 2030
Figure 5: Next-GenerationNext-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Subtype), ($Million), 2020 vs. 2030
Figure 6: Next-Generation Breast Cancer Diagnostics and Screening Market (by End User), ($Million), 2020 vs. 2030
Figure 7: Next-Generation Breast Cancer Diagnostics and Screening Market Snapshot
Figure 2.1: Next-Generation Breast Cancer Diagnostics and Screening Segmentation
Figure 3.1: Primary Research Methodology
Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
Figure 5.1: Number of Cases (in Million) by Different Forms of Cancer, 2018
Figure 5.2: Global Incidence of Breast Cancer Cases, As of 2018
Figure 6.1: Share of Key Developments and Strategies, 2017-2020
Figure 6.2: Product Approval Share (by Company), 2017–2020
Figure 6.3: Product Launch and Upgradation Share (by Company), 2017–2020
Figure 6.4: Synergistic Activities Share (by Company), 2017-2020
Figure 6.5: Funding and Expansion Share (by Company), 2017-2020
Figure 6.6: Mergers and Acquisitions Share (by Company), 2017-2020
Figure 6.7: Other Key Development Share (by Company), 2017-2020
Figure 6.8: Market Share Analysis for the Next-Generation Breast Cancer Diagnostics and Screening Market, 2019
Figure 6.9: Growth Share Matrix for Next-Generation Breast Cancer Diagnostics and Screening (by Company), 2019
Figure 7.1: Next-Generation Breast Cancer Diagnostics and Screening Market (by Technology), ($Million), 2019-2030
Figure 7.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (RT-PCR), ($Million), 2019-2030
Figure 7.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (IHC), ($Million), 2019-2030
Figure 7.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (NGS), ($Million), 2019-2030
Figure 7.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (FISH), (($Million)), 2019-2030
Figure 7.6: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Other), 2019-2030 ($ Million)
Figure 8.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Subtype), ($Million), 2019-2030
Figure 8.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Luminal A), ($Million), 2019-2030
Figure 8.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Luminal B), ($Million), 2019-2030
Figure 8.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Triple-negative/basal-like), ($Million), 2019-2030
Figure 8.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (by HER-2 Enriched), ($Million), 2019-2030
Figure 9.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by Test Type),($Million), 2019-2030
Figure 9.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (BRCA), ($Million), 2019-2030
Figure 9.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (ER/PR Receptor), ($Million), 2019-2030
Figure 9.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (HER-2), ($Million), 2019-2030
Figure 9.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (by Other), ($Million), 2019-2030
Figure 10.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), ($Million), 2020 and 2030
Figure 10.2: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), ($Million), 2019-2030
Figure 10.3: North America Next-Generation Breast Cancer Diagnostic and Screening Market, (($Million)), 2019-2030
Figure 10.4: North America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), ($Million), 2019-2030
Figure 10.5: North America: Market Dynamics
Figure 10.6: U.S. Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
Figure 10.7: Canada Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
Figure 10.8: Europe Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.9: Europe: Market Dynamics
Figure 10.10: Europe Next-Generation Breast Cancer Diagnostics and Screening Market (by Country), ($Million), 2019-2030
Figure 10.11: Germany Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.12: U.K. Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.13: France Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.14: Italy Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.15: Spain Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.16: Rest-of-Europe Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.17: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030,
Figure 10.18: APAC: Market Dynamics
Figure 10.19: APAC Global Next-Generation Breast Cancer Diagnostics and Screening Market (by Country), ($Million), 2019-2030
Figure 10.20: China Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.21: Japan Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.22: India Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.23: Australia Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.24: Singapore Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.25: RoAPAC Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.26: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
Figure 10.27: Latin America: Market Dynamics
Figure 10.28: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), ($Million), 2019-2030
Figure 10.29: Brazil Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million) 2019-2030,
Figure 10.30: Mexico Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030,
Figure 10.31: Rest-of-Latin America Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million) 2019-2030
Figure 10.32: RoW Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030,
Figure 11.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by End User), ($Million), 2019-2030
Figure 11.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Hospital-associated labs), 2019-2030 ($ Million)
Figure 11.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Cancer Research Institutes), ($Million), 2019-2030
Figure 11.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Diagnostic Centers), ($Million), 2019-2030
Figure 11.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (by Other End Users), 2019-2030
Figure 12.1: Total Number of Companies Profiled
Figure 12.2: Abbott Laboratories: Portfolio
Figure 12.3: Abbott Laboratories: Overall Financials, 2017-2019
Figure 12.4: Abbott Laboratories: Revenue (by Segment), 2017-2019
Figure 12.5: Abbott Laboratories: Revenue Split for Diagnostics, 2017-2019
Figure 12.6: Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 12.7: Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 12.8: Abbott Laboratories: SWOT Analysis
Figure 12.9: Agendia: Product Portfolio
Figure 12.10: Agendia: SWOT Analysis
Figure 12.11: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 12.12: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 12.13: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 12.14: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 12.15: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 12.16: Agilent Technologies, Inc.: SWOT Analysis
Figure 12.17: Ambry Genetics: Product portfolio
Figure 12.18: Ambry Genetics: SWOT Analysis
Figure 12.19: Biocept, Inc.: Portfolio
Figure 12.20: Biocept, Inc.: Overall Financials, 2017-2019
Figure 12.21: Biocept, Inc.: Sales (by Segment), 2017-2019
Figure 12.22: Biocept, Inc.: R&D Expenditure, 2017-2019
Figure 12.23: Biocept, Inc.: SWOT Analysis
Figure 12.24: Biotheranostics, Inc.: Product Portfolio
Figure 12.25: Biotheranostics, Inc.: SWOT Analysis
Figure 12.26: CENTOGENE N.V.: Overall Product Portfolio
Figure 12.27: CENTOGENE N.V.: Overall Financials, 2017-2019
Figure 12.28: CENTOGENE N.V.: Sales (by Segment), 2016-2018
Figure 12.29: CENTOGENE N.V.: Sales (by Region), 2017-2019
Figure 12.30: CENTOGENE N.V.: R&D Expenditure, 2017-2019
Figure 12.31: CENTOGENE N.V.: SWOT Analysis
Figure 12.32: Danaher Corporation: Product Portfolio
Figure 12.33: Danaher Corporation: Overall Financials, 2017-2019
Figure 12.34: Danaher Corporation: Revenue (by Business Segment), 2017-2019
Figure 12.35: Danaher Corporation: Revenue (by Region), 2017-2019
Figure 12.36: Danaher Corporation: R&D Expenditure, 2016-2018
Figure 12.37: Danaher Corporation: SWOT Analysis
Figure 12.38: Exact Science Corporation: Product Portfolio
Figure 12.39: Exact Sciences Corporation: Overall Financials, 2017-2019
Figure 12.40: Exact Sciences Corporation: Revenue (by Business Segment), 2017-2019
Figure 12.41: Exact Sciences Corporation: Revenue (by Region), 2017-2019
Figure 12.42: Exact Sciences Corporation: R&D Expenditure, 2017-2019
Figure 12.43: Exact Sciences Corporation: SWOT Analysis
Figure 12.44: F. Hoffmann-La Roche Ltd.: Portfolio
Figure 12.45: F. Hoffmann-La Roche Ltd.: Overall Financials, 2017-2019
Figure 12.46: F. Hoffmann-La Roche Ltd.: Sales (by Segment), 2017-2019
Figure 12.47: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
Figure 12.48: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2017-2019
Figure 12.49: F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 12.50: Fulgent Genetics: Product Portfolio
Figure 12.51: Fulgent Genetics: Overall Financials, 2017-2019
Figure 12.52: Fulgent Genetics: Revenue (by Business Segment), 2018-2019
Figure 12.53: Fulgent Genetics: Revenue (by Region), 2017-2019
Figure 12.54: Fulgent Genetics: R&D Expenditure, 2017-2019
Figure 12.55: Fulgent Genetics: SWOT Analysis
Figure 12.56: Illumina, Inc.: Portfolio
Figure 12.57: Illumina, Inc.: Overall Financials, 2017-2019
Figure 12.58: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 12.59: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 12.60: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 12.61: Illumina, Inc.: SWOT Analysis
Figure 12.62: Invitae Corporation: Overall Product Portfolio
Figure 12.63: Invitae Corporation: Overall Financials, 2017-2019
Figure 12.64: Invitae Corporation: Revenue (by Segment), 2017-2019
Figure 12.65: Invitae Corporation: Revenue (by Geography), 2017-2019
Figure 12.66: Invitae Corporation: R&D Expenditure, 2017-2019
Figure 12.67: Invitae Corporation: SWOT Analysis
Figure 12.68: Lucene Diagnostics Pte Ltd: Product Portfolio
Figure 12.69: Lucene Diagnostic Pte Ltd: SWOT Analysis
Figure 12.70: Myriad Genetics, Inc.: Overall Product Portfolio
Figure 12.71: Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 12.72: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.73: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 12.74: Myriad Genetics, Inc.: SWOT Analysis
